Parsons Capital Management Inc. RI Has $14.42 Million Position in Danaher Co. (NYSE:DHR)

Parsons Capital Management Inc. RI raised its stake in shares of Danaher Co. (NYSE:DHR) by 38.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,807 shares of the conglomerate’s stock after purchasing an additional 17,409 shares during the period. Parsons Capital Management Inc. RI’s holdings in Danaher were worth $14,417,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Fort Pitt Capital Group LLC boosted its position in shares of Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after acquiring an additional 7,421 shares during the period. Good Life Advisors LLC bought a new stake in Danaher in the 3rd quarter valued at $217,000. ORG Partners LLC grew its position in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. increased its holdings in shares of Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after buying an additional 11,216 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR opened at $245.95 on Monday. The business has a fifty day moving average of $235.33 and a 200-day moving average of $253.62. The firm has a market cap of $177.65 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s payout ratio is 20.61%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Royal Bank of Canada lowered their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Barclays lowered their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research note on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.